Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rani Therapeutics Holdings

0.6244
+0.075813.82%
Pre-market: 0.6200-0.0044-0.70%08:08 EDT
Volume:1.11M
Turnover:653.34K
Market Cap:44.87M
PE:-0.69
High:0.6244
Open:0.5590
Low:0.5501
Close:0.5486
52wk High:3.75
52wk Low:0.3870
Shares:71.87M
Float Shares:34.17M
Volume Ratio:2.02
T/O Rate:3.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9027
EPS(LYR):-1.0541
ROE:-1187.52%
ROA:-93.94%
PB:-8.05
PE(LYR):-0.59

Loading ...

BRIEF-Rani Therapeutics Holdings Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing

Reuters
·
Aug 09

Rani Therapeutics Files $200 Million Mixed Shelf

MT Newswires Live
·
Aug 09

Rani Therapeutics files $200M mixed securities shelf

TIPRANKS
·
Aug 09

Rani Therapeutics Holdings Inc Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Aug 09

Rani Therapeutics to Initiate Phase 1 Trial for Oral Obesity Therapy, RT-114, in Second Half of 2025

Reuters
·
Aug 08

Rani Therapeutics Holdings Inc - Phase 1 Study for Rt-114 Expected in H2 2025

THOMSON REUTERS
·
Aug 08

Rani Therapeutics Announces New Securities Purchase Agreement

TIPRANKS
·
Jul 17

Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views

Benzinga
·
Jul 16

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

GlobeNewswire
·
Jul 15

Rani Therapeutics Secures Reduced Warrant Exercise Price Deal with Institutional Investor

Reuters
·
Jul 11

Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business Development

Reuters
·
Jul 07

Rani Therapeutics Holdings Inc. Implements Stockholder-Approved Actions to Expedite Decision-Making

Reuters
·
Jul 01

Rani Therapeutics Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule

Reuters
·
Jun 27

Rani Therapeutics Holdings Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 30

Rani Therapeutics Secures $4.3M via Series D Warrant

TIPRANKS
·
May 20

Rani Therapeutics Holdings Inc. Announces Share Transactions: Issues Series D Warrant and Lowers Exercise Prices for Series B and C Warrants

Reuters
·
May 20

Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating

MT Newswires Live
·
May 16

BRIEF-Rani Therapeutics Q1 Net Income USD -12.738 Million

Reuters
·
May 14

Rani Therapeutics Hldgs Q1 EPS $(0.22) Misses $(0.21) Estimate, Sales $172.00K

Benzinga
·
May 14

Press Release: Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Dow Jones
·
May 14